Cellmid managing director and CEO lifts holding in life sciences company with on-market purchase
Monday, 6 May 2019 Cellmid Limited (ASX:CDY) director Maria Halasz has demonstrated her confidence in the company with the purchase of 39,000 indirect shares at 21 cents a share in on-market trades. The managing director and chief executive officer increased her holding to 1,585,938 fully paid ordinary shares. READ: Cellmid’s évolis Professional product range to be sold in Europe Last month the company registered its évolis Professional anti-ageing hair care products for sale in the European Union and the UK. This represented the final step in a comprehensive regulatory compliance assessment of the products before they could be freely sold in Europe. Cellmid also established a partnership with one of the largest cosmetics retailers in Europe and expects e-commerce sales on the partner’s platform will begin in the first half of the 2020 financial year. READ: Cellmid alopecia patent granted in Europe for évolis hair therapy The évolis Professional product range of all 11 SKUS will be sold in EU member states by Cellmid’s cosmetic retail partner. Consistent with the company’s strategic plan released to the market at the end of February, the EU product registration represents yet another important milestone in the company’s plans for the global expansion of the évolis brand.
Dine Brands has had a rough go since it released its first quarter earnings this week, but CEO Steve Joyce is bullish on his company's future, as evidenced by the company reiterating its full year guidance, and millennials and perennials will lead the push for the company. Dine Brands, which is the...
Business Insider reports that Salesforce is acquiring Tableau. Tableau is a publicly-traded data visualization company. Salesforce is buying the company for $15.7 billion. Tableau's price tag makes it..
E3 2019 is upon us. For those of you who don't know, E3 stands for Electronic Entertainment Expo and it's a highly anticipated conference for video game producers, developers and, of course, players. ..
NEW YORK--(BUSINESS WIRE)--Enzo Biochem, Inc. (NYSE:ENZ), an integrated life sciences company focused on commercializing innovative diagnostic and therapeutics... Business Wire Also reported by •Proactive Investors